ValiRx announces Martin Gouldstone to join its Board as Non-Executive Director

– UK, London – ValiRx Plc (LON: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, today announced the appointment of Martin Gouldstone to its Board as a Non-Executive Director, subject to regulatory due diligence.

“Martin will be an invaluable addition to the Board of ValiRx and his extensive experience in our sector will provide help and advice across all areas of the business. I am delighted that he shares our vision for ValiRx and look forward to working with him.” said Board Chair, Dr. Kevin Cox.

About Martin Gouldstone

Martin Gouldstone is CEO of Oncimmune Holdings plc and has 30 years of corporate finance and business development experience in contract research organizations, healthcare, and pharmaceutical sectors. Previously, Martin was a Global Senior Vice President of Business Development at Owkin, Inc., where he managed commercial teams in the USA and Europe and led new strategic research partnerships. More recently, Martin was CBO at Sensyne Health; Global Senior Vice President and Head of Capital Solutions for Syneos Health; CBO at BenevolentAI.

Martin was previously a Partner at Results Healthcare, where he co-led the healthcare practice; was Head of Lifesciences in the UK for BDO, M&A Lead for Europe at Quintiles (now IQVIA Inc), and held business development and licensing lead roles at Confirmant Ltd and Sareum Holdings PLC. Martin has extensive experience buying and selling deals across Europe and the US, and in negotiating multi-year research partnerships.

Martin Gouldstone is also a Non-Executive Director of hVIVO plc and sits on the Board of Trustees of Orthopaedic Research UK.

Martin Gouldstone holds a BSc in Genetics and has completed a range of postgraduate management courses.

About ValiRx

UValiRx is a life science company focused on early-stage cancer therapeutics and women’s health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework to translate innovative science into clinical development rapidly.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimized development process, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, to achieve a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx’s portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialization.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.